NTEC Is Up 110% In 3 Months – Did You Ride The Rally?

Shares of Intec Pharma Ltd. (NTEC) touched a new 52-week high of $8.08 on Thursday, before closing the day’s trading at $7.84, a gain of 110% in 3 months. The stock was trading around $3.85 when we alerted our premium subscribers to it on September 10, 2018. (Report titled “Is this stock on your radar?”).

Intech’s proprietary drug delivery technology, Accordion Pill, is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism.

The Company has two product candidates in clinical trial stages:

— Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is in pivotal phase III trial for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, dubbed ACCORDANCE.
— AP-cannabinoids, an Accordion Pill to deliver either or both of the primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for various pain indications.

Accordion Pill Carbidopa/Levodopa

Enrolment in the ACCORDANCE trial has been completed, and topline data from this study are expected in mid-2019.

A pharmacokinetic (PK) study of AP-CD/LD 50/500 mg dosed three times per day (TID) in advanced Parkinson’s disease patients is underway, and data from this study are expected by year-end 2018.

AP Cannabinoid

Pharmacokinetic studies of AP-THC are expected to be initiated by this year-end.

Feasibility and Option Agreement:

Early this year, Intec team developed an Accordion Pill for Novartis’ (NVS) proprietary compound.

On Thursday, Novartis and Intec mutually agreed to proceed with the Feasibility and Option agreement program, and a clinical pharmacokinetic study for the Novartis’ compound is expected to commence during the first half of 2019. The details of the therapeutic area or specific compound were not released.

Source: Read Full Article